Multi-parametric MRI-guided focal tumor boost using HDR prostate brachytherapy: A feasibility study

Mason, J.; Al-Qaisieh, B.; Bownes, Peter; Wilson, Dan; Buckley, David L.; Thwaites, David; Carey, B.; Henry, Ann

doi:10.1016/j.brachy.2013.10.011

Cited by 45 publications

(36 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MRI-transrectal ultrasound image fusion has been shown to guide prostate biopsies and identify the location and primary Gleason pattern of lesions in >90% of patients [46]. Currently, image-guided focal RT boost is still in preliminary stages using either SBRT [47,48] or HDR-BT [49,50]. If robotic arm SBRT is proven to be similar to HDR-BT in the coming years, then it too may be used as a boost, akin to how HDR-BT boost has been used to treat certain intermediateand high-risk tumors since 1980s [51].…”

Section: Effectivenessmentioning

confidence: 98%

“…Full-text studies excluded, with reasons Full-text studies excluded, with reasons • Study on HDR-BT boost only (49) • Focus on HDR-BT (11) • Delivery not with robotic arm (5) • Med FU time <1.5 y (1) • Study on dosimetry, physics only (40) • Study on dosimetry, physics only (16) • Study on acute outcomes/toxicity only (6) • Study not on primary or definitive SBRT (1)…”

Section: Efficacymentioning

confidence: 99%

See 1 more Smart Citation

Is robotic arm stereotactic body radiation therapy ‘virtual high-dose rate brachytherapy’ effective for prostate cancer? An analysis of comparative effectiveness using published data

Zaorsky

Hurwitz

Dicker

et al. 2014

Expert Review of Medical Devices

View full text Add to dashboard Cite

High-dose rate brachytherapy (HDR-BT) monotherapy and robotic arm (i.e., CyberKnife) stereotactic body radiation therapy (SBRT) are emerging technologies that have become popular treatment options for prostate cancer. Proponents of both HDR-BT monotherapy and robotic arm SBRT claim that these modalities are as efficacious as intensity-modulated radiation therapy in treating prostate cancer. Moreover, proponents of robotic arm SBRT believe it is more effective than HDR-BT monotherapy because SBRT is non-invasive, touting it as 'virtual HDR-BT.' We perform a comparative effective analysis of the two technologies. The tumor control rates and toxicities of HDR-BT monotherapy and robotic arm SBRT are promising. However, at present, it would be inappropriate to state that HDR-BT monotherapy and robotic arm SBRT are as efficacious or effective as other treatment modalities for prostate cancer, which have stronger foundations of evidence. Studies reporting on these technologies have relatively short follow-up time, few patients and are largely retrospective.

show abstract

Section: Effectivenessmentioning

confidence: 98%

Section: Efficacymentioning

confidence: 99%

Is robotic arm stereotactic body radiation therapy ‘virtual high-dose rate brachytherapy’ effective for prostate cancer? An analysis of comparative effectiveness using published data

Zaorsky

Hurwitz

Dicker

et al. 2014

Expert Review of Medical Devices

View full text Add to dashboard Cite

show abstract

“…16 patients included in an mp-MRI guided focal boost prostate HDR brachytherapy pilot study [6] were retrospectively analysed for this investigation. The patients were aged 57 -77 years, with biopsy proven prostate cancer, stages T1c -T3b, PSA at diagnosis 5 -30 ng/ml, combined Gleason 7 -9.…”

Section: Methodsmentioning

confidence: 99%

“…This was done at the time of brachytherapy treatment for the pre-treatment MRI scans, with the delineated F-GTV fused to TRUS to perform focal boost treatments. For the focal boost treatments a 4.5mm margin in all directions (constrained to avoid the urethra and remain inside the prostate capsule) was applied to the F-GTV to generate an F-PTV, on the TRUS images, to allow for tumour delineation and image registration uncertainties [6]. Staging scans were delineated more than one year after the last patient treatment for this retrospective planning study.…”

Section: Methodsmentioning

confidence: 99%

“…Tumour control probability may be improved with a focal boost treatment where the whole gland is treated to the standard dose prescription and a focal boost dose is given to the dominant intra-prostatic lesion (DIL) [1,2] or other CTV sub-volume as described in GEC-ESTRO recommendations [3]. Focal boost treatments in high dose rate (HDR) prostate brachytherapy [4][5][6][7] typically use multi-parametric-MRI (mp-MRI) for tumour delineation; this is then fused to images acquired after needle insertion for treatment planning. Targeting of the focal boost dose is therefore impacted by uncertainties in tumour delineation and image fusion.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of focal boost high dose rate prostate brachytherapy optimisation methods

Mason¹,

Bownes²,

Carey³

et al. 2015

Radiotherapy and Oncology

Self Cite

View full text Add to dashboard Cite

MRI‐TRUS registration methodology for TRUS‐guided HDR prostate brachytherapy

McGeachy

Watt

Husain

et al. 2021

J Applied Clin Med Phys

View full text Add to dashboard Cite

Purpose: High-dose-rate (HDR) prostate brachytherapy is an established technique for whole-gland treatment. For transrectal ultrasound (TRUS)-guided HDR prostate brachytherapy, image fusion with a magnetic resonance image (MRI) can be performed to make use of its soft-tissue contrast. The MIM treatment planning system has recently introduced image registration specifically for HDR prostate brachytherapy and has incorporated a Predictive Fusion workflow, which allows clinicians to attempt to compensate for differences in patient positioning between imaging modalities. In this study, we investigate the accuracy of the MIM algorithms for MRI-TRUS fusion, including the Predictive Fusion workflow.Materials and Methods: A radiation oncologist contoured the prostate gland on both TRUS and MRI. Four registration methodologies to fuse the MRI and the TRUS images were considered: rigid registration (RR), contour-based (CB) deformable registration, Predictive Fusion followed by RR (pfRR), and Predictive Fusion followed by CB deformable registration (pfCB). Registrations were compared using the mean distance to agreement and the Dice similarity coefficient for the prostate as contoured on TRUS and the registered MRI prostate contour.Results: Twenty patients treated with HDR prostate brachytherapy at our center were included in this retrospective evaluation. For the cohort, mean distance to agreement was 2.1 ± 0.8 mm, 0.60 ± 0.08 mm, 2.0 ± 0.5 mm, and 0.59 ± 0.06 mm for RR, CB, pfRR, and pfCB, respectively. Dice similarity coefficients were 0.80 ± 0.05, 0.93 ± 0.02, 0.81 ± 0.03, and 0.93 ± 0.01 for RR, CB, pfRR, and pfCB, respectively. The inclusion of the Predictive Fusion workflow did not significantly improve the quality of the registration. Conclusions:The CB deformable registration algorithm in the MIM treatment planning system yielded the best geometric registration indices. MIM offers a commercial platform allowing for easier access and integration into clinical departments with

show abstract

Multi-parametric MRI-guided focal tumor boost using HDR prostate brachytherapy: A feasibility study

Cited by 45 publications

References 25 publications

Is robotic arm stereotactic body radiation therapy ‘virtual high-dose rate brachytherapy’ effective for prostate cancer? An analysis of comparative effectiveness using published data

Is robotic arm stereotactic body radiation therapy ‘virtual high-dose rate brachytherapy’ effective for prostate cancer? An analysis of comparative effectiveness using published data

Comparison of focal boost high dose rate prostate brachytherapy optimisation methods

MRI‐TRUS registration methodology for TRUS‐guided HDR prostate brachytherapy

Contact Info

Product

Resources

About